Investigational drug · Phase 3
AD-233C
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Type 2 Diabetes Mellitus (T2DM).
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "AD-233C"
First trial start
2026
Sep 30, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AD-233C", any sponsor or status.
Conditions studied
As listed on its trial records.
- Type 2 Diabetes Mellitus (T2DM)
Approved drugs for the same conditions: Type 2 diabetes · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "AD-233C" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safety of AD-233A, AD-233B, AD-233C and/or AD-233D Combination TherapyPivotal-lookingNot yet recruiting
Addpharma Inc.Industry
NCT07816198 · 354 participants (planned) · Start Sep 30, 2026 · Primary completion Jun 30, 2028
Drug: AD-233A; AD-233B and 4 more · For: Type 2 Diabetes Mellitus (T2DM)
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Type 2 Diabetes Mellitus (T2DM)
- BofanglutideGZR18, BofanglutidaPhase 311 trials
Gan & Lee Pharmaceuticals. · Type 2 Diabetes Mellitus (T2DM), Obstructive Sleep Apnea (OSA), Obesity/Overweight in Adult
- MWN109 1Phase 36 trials
Shanghai Minwei Biotechnology Co., Ltd · Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM)
- MWN109 2Phase 36 trials
Shanghai Minwei Biotechnology Co., Ltd · Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM)
- MWN109 3Phase 35 trials
Shanghai Minwei Biotechnology Co., Ltd · Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM)
- BGM0504 AdministeredPhase 32 trials
BrightGene Bio-Medical Technology Co., Ltd. · Type 2 Diabetes Mellitus (T2DM)
- AD-233APhase 31 trial
Addpharma Inc. · Type 2 Diabetes Mellitus (T2DM)
- AD-233BPhase 31 trial
Addpharma Inc. · Type 2 Diabetes Mellitus (T2DM)
- AD-233DPhase 31 trial
Addpharma Inc. · Type 2 Diabetes Mellitus (T2DM)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.